[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"radiation-therapy-complication\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:radiation-therapy-complication":26},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,4,0,[8,41,67,91],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":4,"eligibilityCriteria":14,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":4,"enrollmentInfo":17,"targetDuration":4,"studyType":20,"phases":21,"briefSummary":23,"conditions":24,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":29,"lastUpdatePostDateStruct":30,"startDateStruct":33,"completionDateStruct":35,"leadSponsor":37,"locationsCount":40},"100627381","early-pelvic-floor-physical-therapy-for-women-undergoing-pelvic-radiation-for-gynecologic-malignancies-100627381",false,"NCT07447895","Early Pelvic Floor Physical Therapy for Women Undergoing Pelvic Radiation for Gynecologic Malignancies","Inclusion Criteria:\n\n1. Participants must be female.\n2. Patients must be 18 years old or older.\n3. Any patient with invasive cervical cancer who is planned for definitive chemoradiation.\n4. Plan to receive a minimum dose of 45Gy to pelvis per investigator.\n5. Willing to undergo pelvic floor physical therapy.\n\nExclusion Criteria:\n\n1. Any previous therapeutic pelvic radiation.\n2. Non-English speaking.","FEMALE","18 Years",{"count":18,"type":19},28,"ESTIMATED","INTERVENTIONAL",[22],"NA","This is a single arm phase II study in which 28 patients who will be undergoing definitive pelvic external beam radiation therapy for cervical cancer will receive pelvic floor physical therapy 4 weeks after completing radiation therapy.",[25,26,27],"Cervical Cancer","Radiation Therapy Complication","Pelvic Floor Disorders","RECRUITING","2026-04-20",{"date":31,"type":32},"2026-04-23","ACTUAL",{"date":34,"type":32},"2026-04-16",{"date":36,"type":19},"2030-04-16",{"name":38,"class":39},"University of Cincinnati","OTHER",1,{"id":42,"slug":43,"hasResults":11,"nctId":44,"briefTitle":45,"officialTitle":46,"acronym":47,"eligibilityCriteria":48,"healthyVolunteers":11,"sex":49,"minAge":16,"maxAge":4,"enrollmentInfo":50,"targetDuration":4,"studyType":52,"phases":4,"briefSummary":53,"conditions":54,"keywords":4,"overallStatus":57,"whyStopped":4,"lastUpdateSubmitDate":58,"lastUpdatePostDateStruct":59,"startDateStruct":61,"completionDateStruct":63,"leadSponsor":65,"locationsCount":4},"100623128","validation-of-pet-questionnaire-for-experience-and-sustainability-in-telemedicine-petpatient-experience-in-telehealth-100623128","NCT07392606","Validation of PET Questionnaire for Experience and Sustainability in Telemedicine. PET(Patient Experience in Telehealth)","Assessment of Patient Experience in Telemedicine: Validation of the Co-designed \"Patient Experience in Telehealth (PET)\" Questionnaire to Measure Experience and Assess Environmental, Economic and Organizational Impact.","PET","Inclusion Criteria:\n\n* Age ≥18 years\n* Receipt of at least one telemedicine service at FPG IRCCS\n* Provision of informed consent to participate in the study.\n\nExclusion Criteria:\n\n* Cognitive or linguistic difficulties preventing comprehension of the questionnaire, in the absence of an available caregiver to provide assistance.\n* Exclusive use of telemonitoring services or asynchronous reporting, as the survey focuses on synchronous interactions (e.g., video consultation).","ALL",{"count":51,"type":19},200,"OBSERVATIONAL","Background: Telemedicine adoption has expanded rapidly in recent years, creating new opportunities for access to care, particularly for frail patients or those with mobility limitations. However, the large-scale deployment of remote healthcare services has highlighted the lack of validated instruments to systematically and multidimensionally assess patients' subjective experience. Patient experience is recognized as a key indicator of quality of care, with direct implications for treatment adherence, appropriate use of digital health technologies, and the effectiveness of organizational care models.\n\nRationale: No instruments have been specifically validated in Italy to measure patient experience in telemedicine. In response, the Fondazione Policlinico Universitario A. Gemelli - Istituto di Ricovero e Cura a Carattere Scientifico (FPG IRCCS) developed, through a co-design process involving expert patients and healthcare professionals, the Patient Experience in Telehealth questionnaire (PET). The tool was designed to capture not only overall satisfaction, but also relational, informational, and organizational domains, as well as perceived economic and environmental impact.\n\nObjectives: The primary objective is psychometric validation of PET, assessing reliability and validity (construct, convergent, and discriminant). Secondary objectives include evaluating the perceived impact of telemedicine on care organization, patient-borne costs, and the environment, and exploring differences according to sociodemographic variables.\n\nMethods: This cross-sectional observational study will administer PET to at least 200 adult patients who received one or more telemedicine services at FPG IRCCS within the preceding three months. Content validity will be assessed by an expert panel. Descriptive analyses, exploratory factor analysis (EFA), confirmatory factor analysis (CFA), and reliability testing will be performed. A subgroup will complete a test-retest assessment after 7-14 days.\n\nHypothesis: PET is expected to demonstrate satisfactory psychometric properties, discriminate across different levels of patient experience, and capture the perceived organizational, economic, and environmental impacts of telemedicine in healthcare delivery.",[55,56,26],"IBD","Arrythmia","NOT_YET_RECRUITING","2026-01-29",{"date":60,"type":32},"2026-02-06",{"date":62,"type":19},"2026-02-01",{"date":64,"type":19},"2027-02-01",{"name":66,"class":39},"Fondazione Policlinico Universitario Agostino Gemelli IRCCS",{"id":68,"slug":69,"hasResults":11,"nctId":70,"briefTitle":71,"officialTitle":71,"acronym":4,"eligibilityCriteria":72,"healthyVolunteers":11,"sex":15,"minAge":73,"maxAge":74,"enrollmentInfo":75,"targetDuration":77,"studyType":52,"phases":4,"briefSummary":78,"conditions":79,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":82,"lastUpdatePostDateStruct":83,"startDateStruct":85,"completionDateStruct":87,"leadSponsor":89,"locationsCount":40},"100508996","prospective-observational-study-on-outcome-of-high-precision-hypo-fractionated-radiotherapy-in-metastatic-breast-cancer-precise-m-100508996","NCT05907681","Prospective Observational Study on Outcome of High-precision Hypo-fractionated Radiotherapy in Metastatic Breast Cancer (PRECISE-M)","Inclusion Criteria:\n\n* histologically confirmed breast cancer\n* presence of distant metastasis\n* radiation therapy using IMRT, SBRT, or proton therapy is done or planned\n* Able and willing to comply with the study protocol\n\nExclusion Criteria:\n\n* unable to adhere to the study protocol","19 Years","100 Years",{"count":76,"type":19},400,"5 Years","This study is a prospective observational study on outcomes of high precision hypo-fractionated radiotherapy in breast cancer with distant metastasis.",[80,81,26],"Breast Cancer","Metastatic Breast Cancer","2025-06-27",{"date":84,"type":32},"2025-06-29",{"date":86,"type":32},"2023-05-11",{"date":88,"type":19},"2033-12-31",{"name":90,"class":39},"Samsung Medical Center",{"id":92,"slug":93,"hasResults":11,"nctId":94,"briefTitle":95,"officialTitle":95,"acronym":96,"eligibilityCriteria":97,"healthyVolunteers":11,"sex":49,"minAge":16,"maxAge":4,"enrollmentInfo":98,"targetDuration":4,"studyType":20,"phases":100,"briefSummary":101,"conditions":102,"keywords":105,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":110,"lastUpdatePostDateStruct":111,"startDateStruct":113,"completionDateStruct":115,"leadSponsor":117,"locationsCount":40},"100382945","surface-monitoring-technology-to-remove-the-mask---stage-1-100382945","NCT04266223","Surface Monitoring Technology to Remove The Mask - Stage 1","SMART","Inclusion Criteria\n\n* A diagnosis of head and neck cancer, any stage\n* ≥ 18 years of age\n* ECOG performance status 0-2\n* Receiving radiation therapy for HNC with a thermoplastic immobilisation mask\n* Any other prior therapy allowed\n* Willing and able to comply with all study requirements\n* Must be able to read and complete questionnaires in English\n\nExclusion Criteria\n\n* People with cognitive impairment which would preclude them from providing informed consent\n* People who are unable to speak and read English and for whom obtaining consent would be difficult.\n\nWithdrawal Criteria\n\n* Participants may withdraw from the study at any time before, during or after participation, and do not have to provide a reason. They may do so by advising any member of the study team, research office or their treating team, by completing the withdrawal of consent form, verbally or in writing.\n* Participants may be withdrawn from the study by the principal investigator, treating physician or attending clinician if they perceive the participant is experiencing or will likely experience physical or mental harm\n* No additional study data will be collected for a participant after they withdraw from the study\n* Withdrawing participants' data will be used unless the participant specifies they no longer give permission for the data to be stored or used, however, their data will not be removed from any analysis or publication that has already occurred, or from study databases once it has been de-identified\n* Participant will be replaced if they withdraw or are withdrawn from the study prior to starting the second couch session. This will be done by recruitment of an additional participant.\n* If a couch session is ended by the researcher or participant for reasons unrelated to the study (e.g. not related to equipment failure or participant non-acceptance), the session may be rescheduled, or participant replaced.\n* Reasons for withdrawal will be reported in any outcome publications.",{"count":99,"type":19},20,[22],"A pilot-stage device feasibility study investigating a mask-free motion-monitoring patient immobilisation system for use during radiation therapy treatment of head and neck cancer (HNC). This mask-free system combines the standard radiation therapy (RT) head rest to help the patient remain still with a surface guidance detection system that uses sensors to detect and track patient movement.\n\nPatients who will have RT treatment for head and neck cancer involving an immobilisation mask will be asked to lie on the treatment couch for the normal treatment fraction time while the surface monitoring system is activated. We will then assess:\n\ni) The level of acceptance of the system by HNC patients currently being treated with RT using an immobilisation mask, and ii) The ability of the surface guidance system to monitor movement of the patients",[103,26,104],"Head and Neck Cancer","Anxiety",[106,107,104,108,109],"Radiation Therapy","Mask","Motion sickness","Claustrophobia","2024-07-08",{"date":112,"type":32},"2024-07-09",{"date":114,"type":32},"2023-03-28",{"date":116,"type":19},"2024-12",{"name":118,"class":39},"University of Sydney"]